Anti-hCD47 antibodies have also been investigated in clinical trials across various types of tumors including B cell lymphomas as therapeutics targeting the CD47-SIRPα axis (12). This evidence concerns the gene SIRPA and B-cell non-Hodgkin lymphoma.